|
|
Article: Mpex's Series B Adds $32M For Work On Antibacterials.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Mpex Pharmaceuticals Inc., which develops bacterial resistance inhibitors in combination with existing antibiotics to treat infections, raised $32 million in its Series B round.
"This financing was, we hope, sufficient to advance the first two products into or through early clinical development," said Bill Gerhart, president and CEO of the San Diego-based company, "as well as provide us with the infrastructure and organizational credibility to attract and obtain additional partnerships for our other programs."
The round was led by Boston-based SV Life Sciences, along with HBM BioVentures Ltd. and HBM BioCapital LPs, both part of ...